Noscira claimed that Phase IIa trial, which was conducted at three centres in Germany considering an advice from experts at the European Medicines Agency (EMA), is the first clinical trial of Nypta (Tideglusib) on a group of Alzheimer’s patients.
The results showed that patients treated with Nypta (Tideglusib) in addition to an acetylcholinesterase inhibitor as base treatment showed a consistent improvement in four of the five clinical efficacy variables that were assessed: Mini Mental State Examination (MMSE), Alzheimer’s Disease Assessment Scale (ADAS-cog), Geriatric Depression State and Global Clinical Assessment. Those variables are cognitive-behavioural scales for confirming and quantifying a person’s mental state.
The improvement was more appreciable in the patients who attained the highest dose and the number of patients that showed stabilisation or improvement in the MMSE scale was significantly greater in the group treated with Nypta (Tideglusib).
Teodoro del Ser, director of clinical development at Noscira has presented the study results at the International Conference on Alzheimer’s Disease (ICAD), held in Honolulu (Hawaii).
In order for these results to be significant, they must be confirmed in a Phase IIb trial in which a larger group of patients are expected to be treated for one year.